ArticleFrontiers in pharmacology2026
Isoalantolactone exhibits activity against
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alveolar echinococcosis (AE) is a severe parasitic disease caused by Methods: Results: ISO promoted phosphoglucose isomerase release, with a half-maximal effective concentration of 16.36 ± 3.24 μM, and reduced germinal cell viability, with a half-maximal inhibitory concentration of 17.46 ± 2.25 μM. It exerted dose- and time-dependent parasiticidal effects, achieving complete protoscolex death within 1-5 days at concentrations of 40 μM and 10 μM, respectively. In infected mice, ISO reduced lesion burden and spleen index and was associated with parasite structural damage, mitochondrial abnormalities, and changes in fibrosis-, inflammation-, and immune-related readouts under the present experimental conditions, with no marked abnormalities in most of the evaluated short-term safety parameters. Conclusion: ISO shows anti-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.